Erratum: Epidermal Growth Factor Receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer (Clinical Cancer Research(2004)10(8594–602)Doi:10.1158/1078-0432.CCR-04-0690)

Bradley A. Schiff, Andrea B. McMurphy, Samar A. Jasser, Maher N. Youne, Dao Doan, Orhan G. Yigitbasi, Seungwon Kim, Ge Zhou, Mahitosh Mandal, Benjamin N. Bekele, FChristopher C. Holsinger, Steven I. Sherman, Sai Ching Yeung, Adel K. El-Naggar, Jeffrey N. Myers

Research output: Contribution to journalComment/debate

Abstract

The editors are publishing this note to alert readers to a concern about this article (1): In Fig. 2B, a splice line is missing in the NPA 187 lane of the b-actin panel.

Original languageEnglish (US)
Number of pages1
JournalClinical Cancer Research
Volume25
Issue number15
DOIs
StatePublished - Aug 1 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Erratum: Epidermal Growth Factor Receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer (Clinical Cancer Research(2004)10(8594–602)Doi:10.1158/1078-0432.CCR-04-0690)'. Together they form a unique fingerprint.

  • Cite this